Humanwell Healthcare (Group) Co.,Ltd. (SHA:600079)

China flag China · Delayed Price · Currency is CNY
20.77
-0.03 (-0.14%)
Oct 24, 2025, 3:00 PM CST
-0.14%
Market Cap33.90B
Revenue (ttm)24.64B
Net Income (ttm)1.37B
Shares Out1.63B
EPS (ttm)0.85
PE Ratio24.47
Forward PEn/a
Dividend0.47 (2.26%)
Ex-Dividend DateAug 19, 2025
Volume10,241,848
Average Volume16,821,419
Open20.81
Previous Close20.80
Day's Range20.68 - 20.87
52-Week Range19.37 - 25.90
Beta0.46
RSI42.04
Earnings DateOct 30, 2025

About SHA:600079

Humanwell Healthcare (Group) Co.,Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. The company offers sufentanil citrate injection, an analgesic drug for combined anesthesia; remifentanil hydrochloride injection for induction of general anesthesia and maintenance of analgesia during general anesthesia; hydromorphone hydrochloride injection for patients who require opioid analgesia; nabuphine hydrochloride injection for use as an analgesic for anesthesia induction; alfentanil hydrochloride injec... [Read more]

Sector Healthcare
Founded 1988
Employees 17,650
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 600079
Full Company Profile

Financial Performance

In 2024, SHA:600079's revenue was 25.44 billion, an increase of 3.71% compared to the previous year's 24.52 billion. Earnings were 1.33 billion, a decrease of -37.70%.

Financial Statements

News

There is no news available yet.